Losing Weight with Insulin Resistance: Why It’s Harder and What Helps

You eat well. You exercise regularly. Yet the scale refuses to budge. If this sounds frustratingly familiar, insulin resistance may be the hidden factor working against you.

Losing weight with insulin resistance is genuinely more difficult than standard weight loss, and it has nothing to do with willpower or effort. It comes down to biology. When your body stops responding properly to insulin, it becomes remarkably efficient at storing fat and remarkably resistant to burning it. Most conventional diet advice simply does not account for this, which is why so many people with insulin resistance feel like they are doing everything right and still failing.

The good news is that once you understand what is happening inside your body, you can make targeted changes that actually work with your metabolism instead of against it. In this guide, you will learn why insulin resistance makes weight loss harder, which common mistakes tend to backfire, and which practical strategies are backed by science to help your body start responding again. No complicated jargon, no overwhelming protocols. Just clear, actionable steps you can start using today.

What Is Insulin Resistance?

Insulin resistance is a metabolic condition in which cells in your muscle, fat, and liver tissue gradually lose their ability to respond effectively to insulin, a hormone produced by the pancreas. Under normal circumstances, insulin acts like a key, unlocking cells so they can absorb glucose from the bloodstream and use it for energy. When those cells stop responding to insulin signals as efficiently, the pancreas must produce increasingly larger amounts of insulin to achieve the same glucose-clearing effect. Think of it like turning up the volume on a radio that is slowly losing its sensitivity; the signal is still being sent, but more power is required to get the same result. According to StatPearls via the National Institutes of Health, this impaired cellular response is the defining feature of insulin resistance and the starting point for a cascade of metabolic changes.

To compensate for this reduced sensitivity, the pancreas works harder, releasing greater amounts of insulin into the bloodstream in a process known as compensatory hyperinsulinemia. In the early stages, this compensation is often remarkably effective, keeping fasting blood glucose levels within a normal range and masking the underlying problem entirely. However, maintaining that compensation comes at a cost. A chronically elevated insulin environment drives fat storage, particularly around the abdomen, promotes inflammation, disrupts cholesterol and triglyceride levels, and raises cardiovascular risk over time. As the NIDDK explains, hyperinsulinemia itself can further worsen insulin resistance, creating a self-reinforcing cycle that quietly progresses in the background.

The condition is far more widespread than most people realize, which is important context if you are currently navigating it. Approximately 1 in 3 US adults has insulin resistance, according to the Obesity Medicine Association, and among adults aged 18 to 44, that figure rises to roughly 4 in 10. A 2025 systematic review and meta-analysis published in Frontiers in Endocrinology, drawing on 87 studies and 235,148 participants, estimated a global pooled prevalence of 26.53% among adults. Insulin resistance is not a rare or unusual diagnosis; it is a common metabolic state affecting hundreds of millions of people worldwide.

One reason so many cases go undetected is that early insulin resistance produces few, if any, noticeable symptoms. The pancreas compensates quietly, and standard annual bloodwork, including fasting glucose and A1C testing, frequently misses the condition unless fasting insulin levels are measured alongside those markers to calculate a value called HOMA-IR. Some individuals notice subtle signs such as persistent fatigue after meals, strong carbohydrate cravings, difficulty losing weight despite consistent effort, or patches of darkened skin, but these are nonspecific and easy to attribute to other causes. Requesting a more complete metabolic panel, including fasting insulin, is often necessary to get a clear picture.

It is also worth understanding that insulin resistance is not a binary condition; it exists on a spectrum. Mild impairment can be fully compensated, with blood glucose appearing normal on standard tests. As resistance deepens and the pancreas struggles to keep up, glucose levels begin to rise into the prediabetes range. Left unaddressed, the condition can progress to type 2 diabetes when the pancreas can no longer compensate adequately. Identifying insulin resistance early, before that progression occurs, is clinically significant because early intervention through targeted nutrition, physical activity, weight management, and medical support can meaningfully improve insulin sensitivity and shift the trajectory in a more favorable direction.

Why Insulin Resistance Makes Weight Loss So Difficult

Understanding why the scale resists moving when insulin resistance is present requires looking beyond simple calorie math. The challenge is biochemical, hormonal, and self-reinforcing in ways that conventional weight loss advice rarely addresses.

Insulin as a Fat-Storage Hormone

Insulin is far more than a blood sugar regulator. When circulating insulin levels remain chronically elevated, as they do in insulin resistance (because the pancreas keeps producing more to compensate for reduced cellular response), the body enters a persistent fat-storage state. Elevated insulin signals adipose cells to absorb and store energy as triglycerides, while simultaneously suppressing lipolysis, the metabolic process by which stored fat is broken down into fuel. This suppression occurs at the biochemical level, with insulin activating enzymes that effectively switch off the fat-mobilization pathway. The practical result is that even when caloric intake is reduced, high circulating insulin keeps the body’s “fat-release switch” in the off position, limiting how efficiently stored fat can actually be used for energy.

Visceral Fat: A Consequence and a Cause

The fat that accumulates under these hormonal conditions tends to concentrate around the abdominal organs, a type known as visceral fat. This is significant because visceral fat is not metabolically inert. It actively releases inflammatory compounds, including cytokines like TNF-alpha, that further impair the body’s ability to respond to insulin. In this way, elevated insulin promotes visceral fat accumulation, and that same visceral fat then deepens insulin resistance. A larger waist circumference is one of the most consistent clinical indicators of both elevated visceral fat and worsening metabolic function, according to research published in Frontiers in Endocrinology.

Hunger Signals Working Against You

Insulin resistance also disrupts appetite regulation in ways that make dietary adherence genuinely difficult. When insulin spikes sharply after meals and then drops, blood glucose becomes volatile. These swings send strong hunger signals to the brain and trigger cravings specifically for fast-digesting carbohydrates and sugary foods, the very foods most likely to spike insulin again. This is not a matter of willpower. It is a physiological feedback loop that consistently undermines calorie control even among highly motivated individuals.

The Paradox of Doing Everything Right

Perhaps the most frustrating dimension of losing weight with insulin resistance is what might be called the fat-burning suppression paradox. A person can follow conventional guidance, reducing calories, exercising regularly, and tracking intake meticulously, and still see limited fat loss. The reason is that elevated insulin biochemically obstructs fat oxidation regardless of energy intake. Muscle tissue, which is one of the body’s primary sites for glucose disposal, becomes less responsive, reducing metabolic flexibility further. This hormonal override explains why the standard calorie-in, calorie-out framework consistently underperforms for people with insulin resistance.

The Self-Reinforcing Cycle

All of these mechanisms connect into a compounding loop. Insulin resistance promotes fat storage, particularly visceral fat. Visceral fat generates inflammatory signals that worsen insulin sensitivity. Worsening insulin sensitivity drives higher compensatory insulin output, which accelerates further fat accumulation. Each turn of this cycle makes the next one harder to interrupt using standard approaches alone. Breaking it requires strategies specifically designed to lower insulin levels, improve cellular sensitivity, and reduce visceral fat, rather than simply eating less and moving more. Recognizing this cycle is the first step toward addressing it effectively.

What a Medical Evaluation Can Tell You

Because insulin resistance often develops quietly over years, many people arrive at a weight loss program without a clear picture of their metabolic health. A structured medical evaluation changes that. It provides objective data on what is actually happening at a hormonal and metabolic level, which is the only reliable starting point for building an effective, personalized plan.

The Markers That Matter Most

Several diagnostic tools work together to assess insulin resistance, and each tells a different part of the story. Fasting glucose measures how much sugar remains in your bloodstream after an overnight fast, with values between 100 and 125 mg/dL suggesting impaired fasting glucose. Hemoglobin A1C reflects average blood sugar over the prior two to three months and flags prediabetes at 5.7 to 6.4 percent. A lipid panel, particularly elevated triglycerides above 150 mg/dL and low HDL cholesterol, points toward metabolic dysfunction commonly associated with insulin resistance. Waist circumference, often greater than 40 inches in men or 35 inches in women, serves as a practical proxy for visceral fat, the type most closely linked to metabolic risk.

Critically, fasting insulin is one of the most informative markers available, yet it is frequently left off standard annual panels. When the pancreas is working overtime to compensate for reduced cellular sensitivity, fasting insulin rises well before glucose or A1C readings leave the normal range. Requesting this test, and calculating the HOMA-IR index from the result, can surface insulin resistance years before other markers become abnormal.

Why Numbers Require Context

Raw lab values are only as useful as the clinician interpreting them. A fasting glucose of 98 mg/dL reads as “normal” on a standard report, but if it is accompanied by elevated fasting insulin, a high triglyceride-to-HDL ratio, a waist circumference above threshold, and symptoms like persistent fatigue or difficulty losing weight despite effort, the full picture is meaningfully different. A licensed prescriber can weigh those data points alongside family history, sleep quality, stress levels, and body composition to reach a far more accurate assessment than any single lab value provides.

This interpretive layer is what separates a screening from a genuine evaluation, and it is also what makes a medically supervised program the more clinically sound choice. When labs are part of the intake process rather than an afterthought, interventions can be matched to an individual’s specific metabolic status from the very beginning. Progress can then be tracked objectively over time, using the same markers as benchmarks. That structure turns weight management into something measurable and responsive rather than a process of guessing and adjusting without direction.

Nutrition: Eating for Insulin Sensitivity

What you eat has a direct and measurable impact on how your body produces and responds to insulin. For anyone working on losing weight with insulin resistance, dietary strategy matters as much as calorie quantity. The goal is not simply eating less but eating in a way that supports stable blood glucose, reduces excessive insulin release, and creates conditions where fat burning becomes physiologically possible.

Prioritize protein at every meal. Dietary protein from sources like eggs, fish, lean poultry, legumes, and low-fat dairy promotes satiety more effectively than refined carbohydrates, which means you feel fuller for longer without consuming excess calories. Protein also preserves lean muscle mass during a caloric deficit, which is particularly important because muscle tissue is one of the primary sites where glucose is cleared from the bloodstream. Perhaps most relevant to managing insulin resistance, protein has a considerably lower insulin-stimulating effect compared to refined carbohydrates and added sugars. Aiming for roughly 20 to 30 grams of protein per meal provides a practical starting point, though individual needs vary.

Choose fiber-rich carbohydrates over refined ones. Whole grains, legumes, non-starchy vegetables, and most fruits slow the rate at which glucose enters the bloodstream, blunting the sharp post-meal insulin spikes that are common in insulin-resistant individuals. Fiber also supports the gut microbiome in ways that appear to benefit metabolic health over time. Refined carbohydrates and foods with added sugars produce the opposite effect, driving rapid glucose elevation and demanding a larger insulin response. MD Anderson’s nutrition guidance for insulin resistance consistently emphasizes swapping processed, high-glycemic foods for whole-food carbohydrate sources as a foundational step.

Use healthy fats strategically. Unsaturated fats from olive oil, avocados, nuts, and seeds do not trigger significant insulin release and contribute meaningfully to satiety, which supports overall calorie regulation. Including these fats as part of a balanced meal, rather than relying on high-glycemic foods to feel satisfied, helps maintain more stable glucose and insulin dynamics throughout the day.

Structure your meal timing. Irregular eating patterns, skipping meals and then overeating later, and frequent unplanned snacking all introduce unnecessary blood sugar volatility. Research supports consistent, structured meal timing, with balanced meals spaced several hours apart and dinner ideally consumed a few hours before bedtime, as a meaningful strategy for improving glucose and insulin stability. The practical framework that emerges from the clinical nutrition research, and one reflected across evidence-based dietary approaches for insulin resistance, is straightforward: build each meal around a protein source, add fiber-rich vegetables or whole-food carbohydrates, include a moderate portion of healthy fat, and minimize refined carbohydrates and added sugars. This structure does not require perfection; it requires consistency over time.

Resistance Training: Building Insulin-Sensitive Muscle

Skeletal muscle is the most metabolically significant tissue in the body when it comes to insulin resistance. Under normal conditions, skeletal muscle accounts for approximately 75 to 80 percent of whole-body glucose disposal in response to insulin, making it the primary site where blood sugar is cleared after meals. The more functional muscle mass you carry, the greater your body’s capacity to pull glucose out of the bloodstream efficiently. This is why building and maintaining muscle is not simply an aesthetic goal for someone with insulin resistance; it is a direct metabolic intervention that works at a cellular level to improve how your body handles glucose every single day.

Aerobic exercise offers real cardiovascular benefits and contributes to calorie expenditure, but resistance training does something distinct: it drives muscle hypertrophy and specifically upregulates the insulin signaling proteins inside muscle cells, including GLUT4 transporters and Akt pathways, that are responsible for glucose uptake. In practical terms, resistance training improves both the quantity and the quality of the muscle tissue available to do metabolic work. Research from Washington University School of Medicine, published in Nature Metabolism, found that participants with obesity and prediabetes who combined supervised exercise with approximately 10 percent weight loss showed more than double the improvement in whole-body insulin sensitivity compared to those who lost weight through diet alone. The evidence strongly supports combining both modalities, rather than choosing one over the other, for maximum metabolic benefit.

That same research carries meaningful implications for prediabetes prevention. Weight loss alone improves insulin sensitivity, but adding structured exercise to a weight loss program substantially amplifies the outcome. For anyone working on losing weight with insulin resistance, this combination represents one of the most powerful lifestyle strategies available.

Getting started does not require a gym membership or advanced fitness knowledge. Bodyweight movements such as squats, glute bridges, push-ups, and lunges are effective entry points. Resistance bands and light free weights expand your options as you progress. Aiming for two to three sessions per week, targeting major muscle groups with one to three sets of eight to fifteen repetitions, is a practical and evidence-supported starting framework. Consistency and gradual progression over time matter far more than starting with heavy loads or high intensity.

One consideration that deserves particular attention: during significant caloric restriction, or for individuals using GLP-1 medications as part of a supervised weight management program, lean muscle preservation becomes a critical priority. Weight loss from any source can include loss of lean mass alongside fat, which can reduce metabolic rate and diminish long-term insulin sensitivity if left unaddressed. Resistance training, paired with adequate protein intake, is the most effective tool for limiting that muscle loss and protecting the metabolic gains achieved through weight reduction.

Sleep and Stress: Two Underestimated Metabolic Levers

Most conversations about losing weight with insulin resistance focus on food and exercise. Those factors matter enormously, but two variables that are just as metabolically significant are routinely treated as secondary concerns: sleep and stress. The research is unambiguous on this point, and the hormonal mechanisms involved are the same ones driving insulin resistance itself.

Sleep has a measurable, quantifiable effect on insulin sensitivity. Experimental studies show that even a single night of partial sleep deprivation can reduce glucose disposal by approximately 20 percent. Four consecutive nights of shortened sleep reduced total-body insulin response by roughly 16 percent and fat-cell insulin sensitivity by as much as 30 percent, a magnitude comparable to differences observed between metabolically healthy individuals and those with obesity or early diabetes. A six-week randomized trial found that restricting sleep to around 6.2 hours per night increased HOMA-IR (a standard measure of insulin resistance) by nearly 15 percent, independent of any change in body weight. Chronic short sleep also elevates cortisol and free fatty acids, both of which further antagonize insulin signaling.

Sleep deprivation compounds insulin resistance through appetite hormones as well. When sleep is insufficient, ghrelin (the hormone that signals hunger) rises while leptin (the hormone that signals fullness) falls. The result is a hormonal environment that drives overeating, and not just any food: the cravings tend to favor high-carbohydrate, quickly absorbed foods that spike blood glucose and demand more insulin. For someone already managing insulin resistance, this effect layers directly on top of existing hunger dysregulation, making dietary discipline significantly harder without addressing the underlying sleep deficit.

Chronic stress introduces a separate but equally direct pathway. Cortisol’s evolutionary purpose is to mobilize glucose rapidly during perceived threats, raising blood sugar to fuel an immediate physical response. Under modern conditions of sustained psychological stress, cortisol remains chronically elevated, keeping blood glucose and insulin levels persistently high. Over time, this promotes the storage of visceral (abdominal) fat, the same fat tissue most strongly associated with worsening insulin resistance. Visceral fat also has a high density of cortisol receptors, creating a feedback loop where stress drives fat storage, and that fat amplifies the stress response.

Practical interventions for both are accessible and evidence-supported. Consistent sleep and wake times, maintained even on weekends, anchor the body’s circadian rhythm and improve sleep quality without medication. Limiting screen exposure in the 30 to 60 minutes before bed reduces blue light interference with melatonin. For stress, brief daily practices such as structured breathing exercises, mindful walking, or short meditation sessions have demonstrated cortisol-lowering effects and support metabolic health when practiced consistently.

These are not peripheral lifestyle suggestions. The American Diabetes Association’s 2025 Standards of Care explicitly position sleep health as a central component of metabolic management, on the same level as nutrition and physical activity. For anyone working on losing weight with insulin resistance, sleep and stress management belong in the core plan.

How Weight Loss Improves Insulin Sensitivity

The relationship between weight loss and insulin sensitivity is not merely correlational; it is measurable, progressive, and grounded in well-documented biological mechanisms. Research published in PMC demonstrates that losing just 5 to 10 percent of body weight produces meaningful improvements in insulin sensitivity and glycemic markers. For someone weighing 200 pounds, that is 10 to 20 pounds. Even at this modest level, improvements appear in liver insulin sensitivity, adipose tissue responsiveness, and beta-cell function, offering early metabolic returns that extend well beyond the number on the scale.

The benefits do not plateau at 5 to 10 percent. Research points to a clear dose-response relationship: weight loss exceeding 10 to 30 percent of body weight is associated with substantially higher rates of insulin resistance remission. A 2025 PMC study examining progressive weight loss found that remission rates increased consistently with the magnitude of loss, reaching notably high levels at greater degrees of reduction. This means that sustained, meaningful weight loss does not simply improve insulin sensitivity incrementally; it can shift the trajectory of metabolic health in ways that modest loss alone may not achieve.

The underlying mechanism explains why these results occur across multiple systems simultaneously. As visceral fat decreases, the adipose tissue releases fewer inflammatory cytokines, liver fat accumulation is reduced, and the hormonal interference that disrupts insulin signaling begins to resolve. Visceral fat is particularly metabolically active and harmful, contributing to ectopic fat deposition in the liver and muscle tissue. Weight loss addresses these drivers in parallel rather than sequentially, which is why its effects on insulin sensitivity can be both broad and lasting.

How that weight loss is achieved also matters considerably. Research from Washington University School of Medicine published in Nature Metabolism found that combining regular exercise with a 10 percent body weight reduction more than doubles whole-body insulin sensitivity compared to achieving the same loss through dietary changes alone. Exercise preferentially reduces visceral and intermuscular fat, enhances muscle glucose uptake, and amplifies the anti-inflammatory effects of caloric reduction. The multi-lever approach is not optional for optimal results; it is the standard the evidence supports.

For many people managing insulin resistance, however, lifestyle effort alone stalls before crossing the threshold where meaningful, sustained sensitivity improvements take hold. Plateaus, adherence challenges, and individual metabolic variation are common. This is precisely where structured medical support can change the outcome, providing the clinical oversight, personalized guidance, and therapeutic options that help people move past the point where effort alone has stopped producing results.

The Role of GLP-1 Medications in IR and Weight Management

For anyone navigating the challenge of losing weight with insulin resistance, GLP-1 receptor agonists represent one of the more significant developments in metabolic medicine in recent decades. These medications work by mimicking glucagon-like peptide-1, a hormone naturally produced in the gut after eating. Once active, they bind to GLP-1 receptors in the brain to signal fullness and reduce appetite, slow gastric emptying to blunt post-meal blood sugar spikes, stimulate glucose-dependent insulin release from the pancreas, and suppress glucagon, the hormone responsible for raising blood glucose between meals. Each of these actions addresses a specific hormonal disruption that makes weight loss difficult when insulin resistance is present, which is why this class of medications has attracted serious clinical attention beyond its original use in blood sugar management.

The evidence supporting GLP-1 medications extends beyond their effect on body weight alone. A 2024 study from Vanderbilt University Medical Center found that a GLP-1 receptor agonist improved insulin sensitivity within two weeks of treatment initiation, before any meaningful weight loss had occurred. Researchers confirmed these benefits were dependent on GLP-1 receptor activation and were not simply a result of elevated natural GLP-1 levels. This points to direct metabolic pathways that operate independently of weight reduction, a meaningful distinction for anyone whose primary barrier to progress is insulin resistance itself.

That said, GLP-1 medications are not a substitute for the lifestyle foundations covered throughout this guide. Their most important role, clinically, is supporting the degree of weight loss necessary to reach the metabolic threshold where meaningful insulin sensitivity improvements occur. Research consistently shows that losing 5 to 10 percent or more of body weight produces measurable changes in how cells respond to insulin. GLP-1 medications can make reaching that threshold more attainable by reducing appetite and improving the body’s hormonal environment, while potentially adding direct benefits through the mechanisms noted above.

On a broader scale, U.S. adult obesity rates declined from a 2022 peak of 39.9 percent to 37.0 percent in 2025, according to Gallup data, with notable drops across multiple age groups during a period of rising GLP-1 use. This is a population-level signal worth acknowledging, even as individual outcomes vary considerably and correlation does not establish cause.

Access to GLP-1 medications requires a thorough medical evaluation by a licensed prescriber. Eligibility, dosing, and ongoing monitoring are determined individually based on a person’s health history, current metabolic markers, and clinical risk profile. These programs are not appropriate for everyone. Physician supervision is not a formality; it is the structure that makes this approach both safe and effective, ensuring that medication is one component of a comprehensive, medically guided plan rather than a standalone solution.

Why a Structured, Medically Supervised Approach Makes Sense

Everything covered in the preceding sections points toward one unavoidable conclusion: insulin resistance is a highly individual condition, and addressing it effectively requires an equally individual approach. Two people can present with nearly identical fasting glucose levels, similar A1C values, and comparable body weight, yet have entirely different underlying drivers, different metabolic histories, different responses to dietary change, and different risk profiles for progression. One person’s insulin resistance may be primarily driven by visceral fat accumulation; another’s may be rooted in years of disrupted sleep, chronic stress, or a family history of metabolic dysfunction. A generic protocol cannot account for those distinctions. Personalized medical evaluation is precisely what separates a plan designed for your biology from one designed for no one in particular.

What a structured, medically supervised program actually includes goes well beyond a single prescription. A comprehensive approach starts with baseline labs to establish a clear metabolic picture, including fasting glucose, insulin levels, lipid panels, HbA1c, and other relevant markers, followed by regular follow-up testing to track how those values respond over time. Board-certified physician oversight guides every meaningful treatment decision, from evaluating candidacy for intervention to adjusting protocols based on how an individual is responding. Certified health coaching provides the consistent, accountable support needed to translate clinical recommendations into sustainable daily habits around nutrition, movement, sleep, and stress. Where clinically appropriate, compounded GLP-1 medications may be made available through licensed, accredited compounding pharmacies, with eligibility and dosing determined individually by a prescribing physician, never as a default.

Certain dietary supplements formulated to support metabolic health, energy, and sleep may also play a supporting role within a structured program as part of a healthy lifestyle. These are not treatments for insulin resistance or any related condition; they are tools that may reinforce the daily habits that matter most, such as supporting energy levels that allow for consistent physical activity or promoting the quality sleep that metabolic recovery depends on.

The contrast with unstructured approaches is worth stating plainly. Self-directed internet research, unsupervised supplement stacking, or obtaining medications without ongoing medical oversight removes the safety layers that a physician-supervised program is specifically built to provide. Risks include improper dosing, undetected contraindications, and gaps in monitoring that matter considerably over time.

For adults who want a medically guided, structured approach to weight management and long-term metabolic health, Elara Health and Wellness offers physician-supervised programs that include labs, health coaching, and compounded GLP-1 access where eligible, with eligibility assessed individually by board-certified physicians.

Moving Forward with Insulin Resistance

Difficulty losing weight with insulin resistance is not a reflection of willpower or effort. It reflects a real physiological mechanism, one that standard weight loss advice was never designed to address. When insulin resistance is present, the body operates under a different set of metabolic rules, and strategies that work for metabolically healthy individuals often fall short for this reason alone.

The path forward involves several well-supported levers working together. A medical evaluation establishes your metabolic baseline and makes personalized planning possible. Nutrition structured around protein and fiber-rich whole foods reduces the insulin demand that drives fat storage. Resistance training builds the kind of metabolically active muscle tissue that absorbs glucose most efficiently. Sleep and stress management remove two underestimated sources of hormonal disruption. And for those who qualify, physician-supervised support including compounded GLP-1 medications can provide meaningful clinical reinforcement when lifestyle changes alone are not sufficient.

Timing also matters. Insulin resistance exists on a spectrum, and acting before it progresses to prediabetes or type 2 diabetes represents the most favorable window for lasting metabolic improvement. That window is not indefinitely open, which makes early, informed action more valuable than waiting for symptoms to worsen.

The most practical first step is a medical evaluation. Understanding where you are metabolically is what makes every other intervention more precise, more targeted, and more likely to produce results that hold over time.